Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$15.32 -1.9%	$14.68	$9.57 ▼ $30.41	$2.16B	0.96	1.54 million shs	2.78 million shs
BBIO BridgeBio Pharma	$41.73 +4.3%	$36.11	$21.62 ▼ $41.94	$7.60B	1.1	2.53 million shs	5.53 million shs
BPMC Blueprint Medicines	$128.20 +0.1%	$104.75	$73.04 ▼ $128.34	$8.27B	0.84	1.26 million shs	4.51 million shs
ROIV Roivant Sciences	$11.45 +0.1%	$10.97	$8.73 ▼ $13.06	$7.78B	1.16	5.68 million shs	18.14 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-1.92%	-2.67%	+0.07%	+3.51%	-35.02%
BBIO BridgeBio Pharma	+4.32%	+4.90%	+27.07%	+20.02%	+51.14%
BPMC Blueprint Medicines	+0.06%	+0.19%	+26.29%	+44.50%	+20.14%
ROIV Roivant Sciences	+0.09%	+1.15%	+4.95%	+6.12%	+5.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.5076 of 5 stars	3.4	1.0	3.4	2.3	2.5	0.0
BBIO BridgeBio Pharma	4.6737 of 5 stars	4.5	2.0	3.9	3.3	3.3	0.6
BPMC Blueprint Medicines	1.0206 of 5 stars	2.1	2.0	0.0	2.0	0.8	0.6
ROIV Roivant Sciences	2.2619 of 5 stars	3.5	3.0	0.0	1.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	185.34% Upside
BBIO BridgeBio Pharma	2.92	Moderate Buy	$56.67	35.79% Upside
BPMC Blueprint Medicines	2.27	Hold	$128.06	-0.11% Downside
ROIV Roivant Sciences	3.00	Buy	$17.50	52.84% Upside

Current Analyst Ratings Breakdown

Latest ARWR, BPMC, BBIO, and ROIV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	595.97	N/A	N/A	$1.54 per share	9.95
BBIO BridgeBio Pharma	$221.90M	35.71	N/A	N/A	($7.71) per share	-5.41
BPMC Blueprint Medicines	$508.82M	16.27	N/A	N/A	$4.70 per share	27.28
ROIV Roivant Sciences	$29.05M	267.95	N/A	N/A	$7.45 per share	1.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	18.37	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.23	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
ROIV Roivant Sciences	-$171.98M	-$0.25	N/A	N/A	N/A	-225.71%	-14.76%	-13.69%	8/6/2025 (Estimated)

Latest ARWR, BPMC, BBIO, and ROIV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
BBIO BridgeBio Pharma	N/A	4.57	4.54
BPMC Blueprint Medicines	1.01	2.80	2.75
ROIV Roivant Sciences	N/A	33.47	33.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BBIO BridgeBio Pharma	99.85%
BPMC Blueprint Medicines	N/A
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
BBIO BridgeBio Pharma	18.20%
BPMC Blueprint Medicines	4.21%
ROIV Roivant Sciences	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
ROIV Roivant Sciences	860	679.81 million	626.10 million	Optionable

ARWR, BPMC, BBIO, and ROIV Headlines

Recent News About These Companies

Assenagon Asset Management S.A. Takes $570,000 Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 20 at 3:44 AM | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Earns "Buy" Rating from HC Wainwright

June 20 at 1:58 AM | americanbankingnews.com

Roivant Sciences (NASDAQ:ROIV) Shares Up 5.4% - What's Next?

June 18 at 2:18 PM | marketbeat.com

HC Wainwright Reiterates Buy Rating for Roivant Sciences (NASDAQ:ROIV)

June 18 at 8:05 AM | marketbeat.com

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

June 16, 2025 | globenewswire.com

Roivant Sciences à la conférence Goldman Sachs : focus sur l’exécution stratégique

June 10, 2025 | fr.investing.com

Roivant Sciences Ltd. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04:00 PM

June 10, 2025 | zonebourse.com

GAMMA Investing LLC Has $6.49 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 10, 2025 | marketbeat.com

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

June 9, 2025 | globenewswire.com

Selon un récent dépôt auprès de la SEC, un initié de Roivant Sciences a vendu des actions pour une valeur de 8 454 808 dollars.

June 7, 2025 | zonebourse.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Vivek Ramaswamy Sells 200,800 Shares

June 7, 2025 | insidertrades.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $2,246,952.00 in Stock

June 6, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Vivek Ramaswamy Sells 547,430 Shares

June 6, 2025 | marketbeat.com

Roivant Sciences Ltd. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 04:20 PM

June 6, 2025 | zonebourse.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $4,801,302.54 in Stock

June 5, 2025 | marketbeat.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 566,278 Shares of Stock

June 5, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $4,801,302.54 in Stock

June 5, 2025 | insidertrades.com

California State Teachers Retirement System Acquires 37,982 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

June 4, 2025 | marketbeat.com

Jefferies Financial Group Inc. Makes New Investment in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 1, 2025 | marketbeat.com

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $324,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 1, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Trading 5.5% Higher - Here's Why

May 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR, BPMC, BBIO, and ROIV Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.32 -0.30 (-1.92%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$15.35 +0.03 (+0.20%)

As of 06/20/2025 07:59 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

BridgeBio Pharma NASDAQ:BBIO

$41.73 +1.73 (+4.33%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$41.60 -0.13 (-0.31%)

As of 06/20/2025 07:57 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Blueprint Medicines NASDAQ:BPMC

$128.20 +0.08 (+0.06%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$128.18 -0.01 (-0.01%)

As of 06/20/2025 08:00 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$11.45 +0.01 (+0.09%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$11.64 +0.20 (+1.70%)

As of 06/20/2025 07:59 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time